Clinical Trials Actively Recruiting

Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below.
Request an Appointment Refer a Patient NCI Dictionary of Cancer Terms Clinical Trials App
Clear Search

Results 1 - 2 of 2

  • Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)

    Objective:

    Primary Objective

    • To determine whether prophylactic radiation therapy (RT) to high-risk asymptomatic bone metastases decreases the occurrence of skeletal-related events (SREs), including pathologic fracture, spinal cord compression, and surgery to bone (not including palliative radiation for pain only), compared to standard of care (SOC).

    Secondary Objectives

    • To compare overall survival (OS) between study arms.
    • To compare occurrence of any SREs (including RT for palliation of pain) among enrolled bone metastasis(es) between study arms.
    • To compare occurrence of hospitalizations related to any SREs in enrolled bone metastasis(es) between study arms.
    • To compare pain-related quality of life (QOL) between study arms.
    • To characterize adverse events of RT and compare to SOC.
    Cancer Categories:
    • Sarcoma
    Principal Investigator:
    • Yeh, Brian
    Karmanos Trial ID:
    • NRG-CC014
    Age Group:
    • Adult
    Phase:
    • Phase III
    Learn More

  • A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects with Non-Oncology Plasma Cell-Related Diseases

    Objective:

    Primary Objective:

    • The primary objective of this study is to assess the safety profile, including any DLT and identification of a MTD (if applicable), to support selection of the RP2D of anito-cel when administered to subjects with GMG.

    Secondary Objectives:

    • To quantify the clinical effect of anito-cel using standard clinical assessments, including Quantitative Myasthenia Gravis (QMG), Myasthenia Gravis Quality of Life (MG QoL 15R), Myasthenia Gravis Activities of Daily Living (MG ADL), MG Composite (MGC), Myasthenia Gravis Foundation of America (MGFA) Class, and MG Post Intervention Status (MG PIS)
    • To determine the change from Baseline in the titer of myasthenia gravis-specific autoantibodies in all subjects following infusion of anito-cel
    • To evaluate the PK in subjects treated with anito-cel in peripheral blood by VCN
    • To characterize the treatment-free interval (period during which no non-steroidal therapy, including immunosuppressive therapy, is required) following cell infusion
    • To characterize the corticosteroid dose reduction following cell infusion
    • To determine the rate of disease related hospitalizations or treatment complications following treatment and descriptively compare to the rate of occurrence prior to treatment
    • To assess for the presence of RCL in subjects
    Cancer Categories:
    • Brain and Nervous System,Sarcoma
    Principal Investigator:
    • Uberti, Joseph
    Karmanos Trial ID:
    • 2025-012
    Age Group:
    • Adult
    Phase:
    • Phase I
    Learn More